Vaxcyte, Inc. PCVX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vaxcyte, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vaxcyte, Inc.'s EPS (diluted)?
- Vaxcyte, Inc. (PCVX) reported EPS (diluted) of -$2.30 in Q1 2026.
- How has Vaxcyte, Inc.'s EPS (diluted) changed year-over-year?
- Vaxcyte, Inc.'s EPS (diluted) decreased by 121.2% year-over-year, from -$1.04 to -$2.30.
- What is the long-term trend for Vaxcyte, Inc.'s EPS (diluted)?
- Over 4 years (2021 to 2025), Vaxcyte, Inc.'s EPS (diluted) has grown at a 30.8% compound annual growth rate (CAGR), from -$1.92 to -$5.62.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.